Literature DB >> 27840011

Inferring rubella outbreak risk from seroprevalence data in Belgium.

Steven Abrams1, Eleni Kourkouni2, Martine Sabbe3, Philippe Beutels4, Niel Hens5.   

Abstract

Rubella is usually a mild disease for which infections often pass by unnoticed. In approximately 50% of the cases, there are no or only few clinical symptoms. However, rubella contracted during early pregnancy could lead to spontaneous abortion, to central nervous system defects, or to one of a range of other serious and debilitating conditions in a newborn such as the congenital rubella syndrome. Before the introduction of mass vaccination, rubella was a common childhood infection occurring all over the world. However, since the introduction of rubella antigen-containing vaccines, the incidence of rubella has declined dramatically in high-income countries. Recent large-scale mumps outbreaks, one of the components in the combined measles-mumps-rubella vaccine, occurring in countries throughout Europe with high vaccination coverage, provide evidence of pathogen-specific waning of vaccine-induced immunity and primary vaccine failure. In addition, recent measles outbreaks affecting populations with suboptimal vaccination coverages stress the importance of maintaining high vaccination coverages. In this paper, we focus on the assessment of rubella outbreak risk using a previously developed method to identify geographic regions of high outbreak potential. The methodology relies on 2006 rubella seroprevalence data and vaccination coverage data from Belgium and information on primary and secondary vaccine failure obtained from extensive literature reviews. We estimated the rubella outbreak risk in Belgium to be low, however maintaining high levels of immunisation and surveillance are of utmost importance to avoid future outbreaks. Copyright Â
© 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Disease outbreaks; Effective reproduction number; Next-generation operator; Serology; Social contact hypothesis; Vaccines

Mesh:

Substances:

Year:  2016        PMID: 27840011     DOI: 10.1016/j.vaccine.2016.10.072

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  5 in total

1.  Benefits and Challenges in Using Seroprevalence Data to Inform Models for Measles and Rubella Elimination.

Authors:  Amy K Winter; Micaela E Martinez; Felicity T Cutts; William J Moss; Matt J Ferrari; Amalie McKee; Justin Lessler; Kyla Hayford; Jacco Wallinga; C Jess E Metcalf
Journal:  J Infect Dis       Date:  2018-07-02       Impact factor: 5.226

2.  Resurgence risk for measles, mumps and rubella in France in 2018 and 2020.

Authors:  Guillaume Béraud; Steven Abrams; Philippe Beutels; Benoit Dervaux; Niel Hens
Journal:  Euro Surveill       Date:  2018-06

Review 3.  Strategies for elimination of rubella in pregnancy and of congenital rubella syndrome in high and upper-middle income countries.

Authors:  E Terracciano; F Amadori; V Pettinicchio; L Zaratti; E Franco
Journal:  J Prev Med Hyg       Date:  2020-04-02

Review 4.  From Genetics to Epigenetics: Top 4 Aspects for Improved SARS-CoV-2 Vaccine Designs as Paradigmatic Examples.

Authors:  Darja Kanduc
Journal:  Glob Med Genet       Date:  2021-11-09

5.  Force of infection of Middle East respiratory syndrome in dromedary camels in Kenya.

Authors:  E G Gardner; S Kiambi; R Sitawa; D Kelton; J Kimutai; Z Poljak; Z Tadesse; S Von Dobschuetz; L Wiersma; A L Greer
Journal:  Epidemiol Infect       Date:  2019-09-24       Impact factor: 2.451

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.